LumiraDx Investor Presentation Deck

Unmet Need for High Sensitivity Troponin POC Test with a ~$900M Addressable Market(1) Intended Use Regulatory Authorization LOQ Clinical Sensitivity Reportable Range Sample Size Sample Type Time to Result lumiraDx™ True POC Needs Aids in diagnosis of MI CE Mark, FDA 510K ≤ 2.0 ng/L I Whole blood (2h): 90%+ I 2.0 − 1,000 ng/L 20μL direct fingerstick Capillary WB, venous blood, plasma Lab Reference Abbott Architect STAT hs- Tnl(2) I ≤10 min Aids in diagnosis of MI CE Mark, FDA 510K ≤3.2 ng/L (specification) 1.5-2.9 ng/L (observed) EDTA Plasma (2-4h): 90.9% 3.2 – 50,000 ng/L 210 μL (on-board) 10 μL (manual dilution) Plasma & serum (LiHep, EDTA) POC Example Siemens Atellica VTLi hs- cTnl (2) Aids in diagnosis of MI CE Mark 2.1 ng/L plasma 3.7 ng/L - WB Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide. Whole blood (2h): 81.3% 2.1 (plasma)/3.7 (WB) - 1,250 ng/L 30-100 μL Capillary WB, venous WB & plasma (LiHep) 18 min (time to first result) (1) Based on our current assumptions, including (a) the existing market sizes, (b) central lab market that could move to POC; and (c) expansion of diagnostic testing. (2) Based on respective company product specifications. 8 min POC Example Triage True hsTnl (²) Aids in diagnosis of MI CE Mark 2.1-3.6 ng/L - plasma 2.8 ng/L - WB EDTA Plasma (2-4h): 91.9% 0.1 – 1,000 ng/L 175 µL Venous WB & plasma (EDTA) 20 min I Key differentiator I 19

View entire presentation